Medicare and other payor criteria may apply. Abbott provides this information as a courtesy and does not guarantee payment or coverage.
* 60-minute warm-up required when starting the sensor.
† Study was performed with the outside US version of the FreeStyle Libre 14 day system. Data is applicable to FreeStyle Libre 2 and 3 systems, as feature sets are similar as FreeStyle Libre 14 day system, excluding alarms.
‡ Patients must meet Medicare eligibility coverage criteria.
§ Data based on total active Medicare patients with CGM readers.
‖ Study was performed with the outside US version of the FreeStyle Libre 2 system. Data is applicable to FreeStyle Libre 2 and FreeStyle Libre 3 systems, as feature sets are similar.
¶ Fingersticks are required if your glucose alarms and readings do not match symptoms or when you see Check Blood Glucose symbol during the first twelve hours.
# Glucose readings are not available during 1-hour warm-up, when sensor is too hot or too cold, when you see an error or "LO" or "HI" message, or no current glucose reading.
** Sensor is water-resistant in up to 1 meter (3 feet) of water. Do not immerse longer than 30 minutes.
†† The user's device must have internet connectivity for glucose data to automatically upload to LibreView and to transfer to connected LibreLinkUp app users.
‡‡ The FreeStyle Libre 3 app and the FreeStyle Libre 3 reader have similar but not identical features. Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol and when your glucose alarms and readings from the system do not match symptoms or expectations.
§§ The FreeStyle Libre systems apps are only compatible with certain mobile devices and operating systems. Please check the Support section of our website for more information about device compatibility before using the apps. Use of the FreeStyle Libre systems apps may require registration with LibreView.
IIII Among patient-applied sensors.
¶¶ The FreeStyle Libre 2 app and the FreeStyle Libre 2 reader have similar but not identical features. Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol and when your glucose alarms and readings from the system do not match symptoms or expectations.
## Notifications will only be received when alarms settings are enabled and turned on and sensor is within 20 feet (FreeStyle Libre 2 system) or 33 feet (FreeStyle Libre 3 system) unobstructed of the reading device.
*** The FreeStyle Libre 2 app also has a mandatory Urgent Low Glucose Alarm that lets users know when their glucose value is below 55mg/dL.
††† Based on retail and DME sales data for the patient’s last-filled prescription, by manufacturer.
‡‡‡ Participating pharmacies and durable medical equipment (DME) suppliers are subject to change without notice.
§§§ Benefits for FreeStyle Libre 2 sensors apply to two FreeStyle Libre 2 sensors. Void where prohibited by law. Abbott may modify, rescind, or revoke these benefits at any time without notice. Offer available to commercially insured patients only. These benefits are not available to beneficiaries of Medicare, Medicaid or other federal or state healthcare programs. For Massachusetts residents, only those patients responsible for the full cost of the product may be eligible to receive these benefits. These benefits are only available at participating pharmacies, which are subject to change without notice. The actual amount a patient pays may vary.
References: 1. Evans, Mark, et al. “The Impact of Flash Glucose Monitoring on Glycaemic Control as Measured by HbA1c: a Meta-analysis of Clinical Trials and Real-World Observational Studies.” Diabetes Therapy 11, no. 1 (2020): 83-95. https://doi.org/10.1007/s13300-019-00720-0. 2. Local Coverage Determination (LCD) L33822, Glucose Monitors, https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=33822. 3. Data on file. Abbott Diabetes Care, Inc. 4. Fokkert, Marion, et al. "Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4)." BMJ Open Diabetes Research and Care 7 (2019): e000809. https://doi.org/10.1136/bmjdrc-2019-000809. 5. Leelarathna, Lalantha, et al. "Intermittently Scanned Continuous Glucose Monitoring for Type 1 Diabetes." New England Journal of Medicine 387, no. 16 (2022): 1477-1487. https://doi.org/10.1056/nejmoa2205650. 6. FreeStyle Libre 3 User's Manual. 7. FreeStyle Libre 2 User’s Manual. 8. Alva, Shridhara, et al. "Accuracy of the third generation of a 14-day continuous glucose monitoring system." Diabetes Therapy 14, no. 4 (2023): 767-776. https://doi.org/10.1007/s13300-023-01385-6. 9. Haak, Thomas, et al. “Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated Type 2 diabetes: a multicentre, open-label randomised controlled trial.” Diabetes Therapy 8, no. 1 (2017): 55-73. https://doi.org/10.1007/s13300-016-0223-6.
ADC-37051 v12.0